PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Protagonist Therapeutics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$134.44+5.69 (+4.42%)
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Protagonist Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.70B | $166.30M |
| Enterprise Value | $7.92B | $88.19M |
| PE Ratio | 130.52 | 20.44 |
| PS Ratio | 30.85 | 3.65 |
| PB Ratio | 10.34 | 2.03 |
| P/TBV Ratio | 10.34 | 2.29 |
| P/FCF Ratio | 66.62 | 17.44 |
| P/OCF Ratio | 66.31 | 12.98 |
Enterprise value
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 28.07 | 2.51 |
| EV / EBITDA | 132.21 | 14.65 |
| EV / EBIT | 135.70 | 19.00 |
| EV / FCF | 60.63 | 20.86 |
Income (trailing twelve months)
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Revenue | $281.99M | $58.34M |
| Operating Income | $58.34M | -$21.40M |
| Pretax Income | $84.34M | -$14.34M |
| Net Income | $82.91M | -$22.46M |
| EBITDA | $59.88M | -$16.91M |
| EPS (Diluted) | $1.03 | -$0.83 |
Margins
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Operating Margin | 20.7% | -44.0% |
| Pretax Margin | 29.9% | -13.3% |
| Profit Margin | 29.4% | -40.2% |
| EBITDA Margin | 21.2% | -30.2% |
| FCF Margin | 46.3% | -9.27% |
Returns
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 11.0% | -53.2% |
| Return on Assets (ROA) | 10.3% | -40.9% |
| Return on Invested Capital (ROIC) | 73.3% | -32.4% |
| Return on Capital Employed (ROCE) | 6.88% | -38.1% |
Growth
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 34.8% | 5.96% |
| Net Income Growth (YoY) | 59.3% | -35.2% |
| EPS Growth (YoY) | 47.1% | -26.2% |
| FCF Growth (YoY) | 252.0% | 2.34% |
| Revenue Growth (3Y CAGR) | 20.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 9.96% | 6.48% |
Balance sheet
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $782.58M | $61.43M |
| Net Cash (Debt) | $782.58M | $15.35M |
| Net Cash Per Share | $12.09 | $0.66 |
| Equity (Book Value) | $841.54M | $49.09M |
| Book Value Per Share | $13.01 | $1.37 |
| Tangible Book Value | $841.54M | $23.52M |
| Working Capital | $769.97M | $76.81M |
Financial position
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 21.71 | 3.34 |
| Quick Ratio | 21.05 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $131.20M | -$12.35M |
| Capital Expenditures | -$615.00K | -$1.08M |
| Free Cash Flow | $130.58M | -$20.22M |
| FCF Per Share | $2.02 | -$0.42 |
Efficiency
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.35 | 0.39 |
| Revenue Per Employee | $2.14M | $404.87K |
| Profits Per Employee | $628.10K | -$703.34K |
| Employee Count | 132 | 74 |
Dividends and yields
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 0.95% | -23.3% |
| FCF Yield | 1.50% | -8.72% |
Shares
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 64,708,300 | 58,127,000 |
| Shares Change (YoY) | 5.73% | 10.9% |
| Shares Change (QoQ) | 0.69% | 0.54% |
| Float | 63,638,800 | 49,136,700 |
| Shares Held by Insiders | 1.65% | 11.6% |
| Shares Held by Institutions | 117.1% | 59.4% |
Taxes
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Income Tax | $1.43M | $79.87K |
| Effective Tax Rate | 1.69% | 20.6% |
Scores
| Measure | Protagonist Therapeutics | Industry median |
|---|---|---|
| Graham Number | $17.36 | $18.73 |
| Graham Upside | -87.1% | -45.1% |
| Altman Z-Score | 119.72 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Protagonist Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.